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ABSTRACT
Elevated blood glucose and increased activities of secreted phospholipase A2 (sPLA2) are strongly linked
to coronary heart disease. In this report, our goal was to develop small heterocyclic compound that inhibit
sPLA2. The title compounds were also tested against a-glucosidase and a-amylase. This array of enzymes
was selected due to their implication in blood glucose regulation and diabetic cardiovascular complica-
tions. Therefore, two distinct series of quinoxalinone derivatives were synthesised; 3-[N0-(substituted-benzy-
lidene)-hydrazino]-1H-quinoxalin-2-ones 3a–f and 1-(substituted-phenyl)-5H-[1,2,4]triazolo[4,3-a]quinoxalin-
4-ones 4a–f. Four compounds showed promising enzyme inhibitory effect, compounds 3f and 4b–d
potently inhibited the catalytic activities of all of the studied proinflammatory sPLA2. Compound 3e inhib-
ited a-glucosidase (IC50¼ 9.99 ±0.18 mM); which is comparable to quercetin (IC50¼ 9.93 ±0.66 mM), a
known inhibitor of this enzyme. Unfortunately, all compounds showed weak activity against a-amylase
(IC50> 200 mM). Structure-based molecular modelling tools were utilised to rationalise the SAR compared
to co-crystal structures with sPLA2-GX as well as a-glucosidase. This report introduces novel compounds
with dual activities on biochemically unrelated enzymes mutually involved in diabetes and its
complications.
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1. Introduction
Impaired function of blood vessels and heart tissues is a common
health problem in diabetic patients1. The individuals with poor
control of their blood glucose suffer from dysregulation of lipid
metabolism leading to deposition of fats in blood vessels2.
Therefore, a new consensus has been created about the underly-
ing lipid metabolic markers in coronary heart disease (CHD)3. In
this regard, phospholipase A2 isozymes have been a focus for
many studies as novel markers of CHD. The super family phospho-
lipase A2 is a hydrolase type of enzyme that specifically releases a
carboxylic acid from sn2 position of glycerophospholipids. The
subfamily secretory phospholipase A2 (sPLA2) is common in
almost all tissues of the mammalian bodies. The hydrolytic activity
of sPLA2s causes the release of poly unsaturated fatty acid arachi-
donic acid (AA) to surrounding tissues. AA is the precursor of the
inflammatory mediators prostaglandins and leukotrienes4.
Dysregulation of sPLA2 function leads to uncontrolled generation
of AA in affected tissues leading to inflammatory disorders such as
sepsis5, asthma6, Alzheimer’s diseases7, atherosclerosis8 and many
others. Chronic elevation of blood glucose leads to increased acti-
vation of sPLA2s, generation of AA and eicosanoids and inflamma-
tory CHD.
Several sPLA2 isozymes have been studied for their implication
in blood glucose regulation through insulin dependent mecha-
nisms. These enzymes are also involved in cardiovascular compli-
cations of diabetes9. For example, sPLA2-GIB promotes insulin
resistance and hyperglycaemia in transgenic mice overexpressing
this enzyme10. Group X sPLA2 is another regulator of insulin pro-
duction, where it suppresses glucose stimulated insulin secretion
from beta cells through a COX-2 dependent mechanism11.
Diabetic subjects were found to be more susceptible to lipolysis
by group V sPLA2 increasing their state of inflammation and
enhancing their risk of cardiovascular complications12. In the light
of their inflammatory and diabetogenic activities, inhibition of
secretory phospholipases is hypothesised to be of value in amelio-
rating the inflammatory and cardiovascular complications of dia-
betes. A very unique characteristic of secretory phospholipases is
their requirement of calcium as a cofactor in high (millimolar) con-
centrations. This property makes them amenable for inhibition via
ligands bearing metal chelating groups. Many of the previously
reported inhibitors of sPLA2 contain a hydrophobic moiety and a
metal chelating group either linked directly or appended to a cen-
tral heterocyclic scaffold13–15.
Diabetic patients suffer from an elevated blood glucose level
that is mediated by a number of interplaying enzymes and biome-
chanisms. Of the major contributors to elevated post-prandial
blood glucose are carbohydrate hydrolases including a-glucosidase
and a-amylase16. These enzymes hydrolyse polysaccharides lead-
ing to the availability of monomeric sugars for absorption, and
thus the elevation of post-prandial blood glucose level17. The
inhibition of such enzymes is therefore of merit for the modula-
tion of post-prandial blood glucose16,18. Many inhibitors have
been reported for such enzymes and are marketed for their anti-
hyperglycemic effect19.
In this work, we are reporting novel heterocyclic sPLA2 inhibi-
tors based on a quinoxalinone scaffold. The synthesised inhibitors
were assayed for their activity against sPLA2 GIB, IIA, V, X, and XII.
To expand our investigation of our compounds’ activities, we also
investigated their ability to inhibit a-glucosidase and a-amylase to
assess their potential in controlling post-prandial blood glu-
cose16,20,21. The inhibition results against the carbohydrate hydro-
lases were compared to quercetin, a flavonoid well known to
inhibit a-glucosidase and a-amylase22–24. We hypothesise that
simultaneous inhibition of this group of interrelated biological tar-
gets may serve as a starting point for a novel small molecule
approach in controlling hyperglycaemia and cardiovascular compli-
cations concomitantly in diabetic patients. This is due to the ability
of these compounds to not only inhibit proatherogenic sPLA2 tar-
gets, but also due to their ability to control hyperglycaemia which
acts as their inducer.
2. Experimental
2.1. Chemistry
The melting points (mp) were determined using a Gallenkamp
melting point apparatus. The IR spectra were recorded in KBr discs
on a PerkinElmer FT-IR (Spectrum BX) spectrophotometer (max in
cm1). 1H and 13C NMR spectra were recorded using a JEOL
Resonance spectrometer (500MHz “megahertz”). Coupling con-
stants are given in Hertz (Hz). Deuterated DMSO-d6 solvent was
obtained from Goss Scientific Instruments (Cheshire, UK). DMSO-d6
was stored in silica gel desiccators. Elemental analysis was carried
out by the microanalysis service using 2mg of the sample (Micro
Analytical Center, Faculty of Science, Cairo University). Spectral
data IR, NMR and Elemental analysis confirmed the structures of
the compounds. The purity of all of the compounds (>95%) was
established by elemental analyses (C, H, N) and results were within
0.4% of the calculated values. All of the known compounds were
identified by comparing their analytical and physicochemical data
with previously reported data. The NMR data for the compounds
are provided in the Supplementary Information.
2.2. General procedure A to the synthesis of 3-[N0-(substituted-
benzylidene)-hydrazino]-1H-quinoxalin-2-one (3a–f)
3-[N0-(substituted-benzylidene)-hydrazino]-1H-quinoxalin-2-one
(3a–f) have been prepared according to Shiho and Tagami30 and
Rashed et al.31, a mixture of 3-hydrazino-1H-quinoxalin-2-one2 and
the corresponding aromatic aldehyde (0.01mol of each) in ethanol
as solvent (20ml) was refluxed for 5 h. Upon cooling, the precipi-
tate was obtained, filtered, dried and purified by column chroma-
tography (8:1.5:0.5 dichloromethane/ethylacetate/ethanol) to give
the desired product.
2.3. General procedure B to the synthesis of 1-(substituted-
phenyl)-5H-[1,2,4]triazolo[4,3-a]quinoxalin-4-ones (4a–f)
1-(Substituted-phenyl)-5H-[1,2,4]triazolo[4,3-a]quinoxalin-4-ones
4a–f have been prepared according to Cheeseman32, mixture of
3a–f (0.02mol) and anhydrous sodium acetate (0.04mol) was
stirred in glacial acetic acid (100ml), then 10% v/v solution of
bromine in glacial acetic acid (10ml) was added in a small portion.
The reaction mixtures were stirred at 25 C for 1 h, and then
poured onto ice water (200ml). The precipitates were filtered
washed with water, followed by aqueous NaHSO3 solution (10%)
(2 50ml). Finally, dried and purified by column chromatography
(8:1.5:0.5 dichloromethane/ethylacetate/ethanol) to give the
desired product.
2.3.1. (E)-3-(2-(3,4,5-trimethoxybenzylidene)hydrazinyl)quinoxalin-
2(1H)-one (3a)
Prepared according to general procedure A. Yield 91%, as a
yellowish orange solid; mp 258–260 C, IR (KBr, cm1) max¼ 3466
(N–H), 3096 (C–H, sp2), 1671 (C¼O), 1566 and 1498 (C¼N).
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1H NMR (500MHz, DMSO-d6) d (ppm): 12.4 (s, 1 H, NHCO), 11.19 (s,
1 H, NH), 8.47 (s, 1 H, CH), 7.52 (s, 1 H, H-60), 7.50 (s, 1H, H-20), 7.18
(dd, 2H, J¼ 11.80Hz, 2.8 Hz, H-6 and H-7), 6.98 (d, 2H, J¼ 12Hz, H-
5 and H-7), 3.37 (s, 3H, 30-OCH3), 3.71 (s, 3H, 40-OCH3), 3.84 (s, 3H,
50-OCH3).
13C NMR (500MHz, DMSO-d6) d (ppm): 157.3, 154.9,
153.2, 150.8, 146.8, 146.1, 145.2, 138.4, 130.3, 128.7, 125.4, 123.5,
115.1, 106.1, 104.1, 60.1, 56.1, and 55.9. Anal. calcd for
C18H18N4O4¼C, 61.01; H, 5.12; N, 15.81; found, C, 61.10; H, 4.85; N,
16.01.
2.3.2. (E)-3-(2-(2,4-dinitrobenzylidene)hydrazinyl)quinoxalin-2(1H)-
one (3b)
Prepared according to general procedure A. Yield 98%, as a red
solid; mp 283–285 C, IR (KBr, cm1) max¼ 3287 (N–H), 3056 (C–H,
sp2), 1673 (C¼O), 1568 and 1522 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.4 (s, 1H, NHCO), 12.00 (s, 1H, NH), 9.06 (s, 1H, CH),
8.76 (dd, 1H, J¼ 15Hz, 2.5 Hz, H-50), 8.55 (dd, 1H, J¼ 6.00 Hz,
2.5 Hz, H-60), 8.42 (s, 1H, H-30), 7.54 (d, 2H, J¼ 7.00 Hz, H-5 and H-
8), 7.22 (m, 2H, H-6 and H-7), 13C NMR (500MHz, DMSO-d6) d
(ppm): 150.6, 147.2, 146.7, 146.1, 139.2, 134.8, 132.2, 129.2, 128.9,
127.4, 126.0, 125.7, 123.6, 120.4, and 115.7. Anal. calcd for
C15H10N6O5¼C, 50.85; H, 2.85; N, 23.72; found; C, 50.54; H, 2.56; N,
23.66.
2.3.3. (E)-3-(2-(2,4-dihydroxybenzylidene)hydrazinyl)quinoxalin-
2(1H)-one (3c)
Prepared according to general procedure A. Yield 85%, as a yellow
solid, mp 292–294 C, IR (KBr, cm1) max¼ 3330 (N–H), 3050 (C–H,
sp2), 1686 (C¼O), 1558 and 1418 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.36 (s, 1H, NHCO), 11.95 (s, 1H, NH), 11.46 (s, 1H,
OH); 9.93 (s, 1H, OH), 8.58 (s, 1H, CH), 7.40 (d,1H, J¼ 3.00 Hz, H-30),
7.19 (m, 4H, H-5 and H-6 and H-7 and H-8), 6.53 (dd, 2H,
J¼ 10.00Hz, 2.5 Hz, H-50 and H-60), 13C NMR (500MHz, DMSO-d6) d
(ppm): 160.3, 159.5, 150.7, 148.4, 145.8, 132.8, 131.4, 128.7, 125.4,
124.6, 123.5, 115.1, 110.9, 107.6, and 102.8. Anal. calcd for
C15H12N4O4!¼C, 57.27; H, 3.81; N, 17.81; found; C, 57.62; H, 3.45; N,
18.02.
2.3.4. (E)-3-(2-(3,4-dichlorobenzylidene)hydrazinyl)quinoxalin-
2(1H)-one (3d)
Prepared according to general procedure A. Yield 67%, as a yellow
solid, mp 244–246 C, IR (KBr, cm1) max¼ 3438 (N–H), 3042 (C–H,
sp2), 1682 (C¼O), 1568 and 1522 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.42 (s, 1H, NHCO). 11.39 (s, 1H, NH), 8.52 (s, 1H,
CH); 8.28 (m, 2H, H-50 and H-60), 7.90 (m, 1H, H-20), 7.20 (m, 4H, H-
5 and H-6 and H-7 and H-8), 13C NMR (500MHz, DMSO-d6) d
(ppm): 172.0, 155.0, 150.7, 146.1, 143.8, 135.6, 131.7, 131.0, 127.9,
115.1, and 115.0. Anal. calcd for C15H10Cl2N4O¼C, 54.07; H, 3.03; N,
16.82; found; C, 54.08; H, 2.81; N, 16.94.
2.3.5. (E)-3-(2-(thiophen-2-ylmethylene)hydrazinyl)quinoxalin-
2(1H)-one (3e)
Prepared according to general procedure A. Yield 66%, as a yellow
solid, mp 260–262 C, IR (KBr, cm1) max¼ 3271 (N–H), 3042 (C–H,
sp2), 1673 (C¼O), 1573 and 1414 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.38 (s, 1H, NHCO), 11.20 (s, 1H, NH), 8.74 (s, 1H,
CH), 7.61 (d, 1H, J¼ 4.5 Hz, H-20), 7.35 (d, 1H, J¼ 3.0 Hz, H-30), 7.19
(d, 1H, J¼ 3.5 Hz, H-40), 7.11–7.17 (m, 4H, H-5 and H-6 and H-7 and
H-8). 13C NMR (500MHz, DMSO-d6) d (ppm): 150.8, 145.9, 141.8,
139.5, 132.8, 129.9, 128.6, 128.3, 127.8, 125.4, 124.6, 123.5, and
122.9. Anal. calcd for C13H10N4OS¼C, 57.76; H, 3.37; N, 20.73;
found; C, 57.63; H, 3.39; N, 20.68.
2.3.6. (E)-3-(2-(3-methoxybenzylidene)hydrazinyl)quinoxalin-2(1H)-
one (3f)
Prepared according to general procedure A. Yield 98%, as a
yellowish orange solid, mp 283–285 C, IR (KBr, cm1) max¼ 3400
(N–H), 3180 (C–H, sp2), 1688 (C¼O), 1567 and 1419 (C¼N). 1H
NMR (500MHz, DMSO-d6) d (ppm): 12.4 (s, 1H, NHCO), 11.22 (s,
1H, NH), 8.55 (s, 1H, CH), 7.53 (s, 1H, H-20), 7.35–7.24 (m, 3H, H-40
and H-50 and H-60), 7.20 (dd, 4H, J¼ 8.25 Hz, 3.5 Hz, H-5 and H-6
and H-7 and H-8), 3.79 (s, 3H, 30-OCH3).
13C NMR (500MHz, DMSO-
d6) d (ppm): 172.0, 159.5, 150.8, 146.6, 139.2, 134.8, 132.2, 129.2,
128.9, 127.4, 126.0, 125.7, 123.6, 120.4, 115.7, and 55.5. Anal. calcd
for C16H14N4O2¼C, 65.30; H, 4.79; N, 19.04; found; C, 65.17; H, 4.42;
N, 18.98.
2.3.7. 1-(3,4,5-Trimethoxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-
4(5H)-one (4a)
Prepared according to general procedure B. Yield 95.7%, as a
white solid, mp 227–229 C, IR (KBr, cm1) max¼ 3418 (N–H), 3072
(C–H, sp2), 1691 (C¼O), 1615 and 1419 (C¼N). 1H NMR (500MHz,
DMSO-d6) d (ppm): 7.40 (m, 2H, H-7 and H-8). 7.27 (s, 2H, H-20 and
H-60). 7.11–7.04 (m, 2H, H-6 and H-9). 3.91 (s, 3H, 30-OCH3), 3.83 (s,
3H, 40-OCH3), 3.78 (s, 3H, 50-OCH3),
13C NMR (500MHz, DMSO-d6) d
(ppm): 153.9, 152.3, 151.5, 149.5, 145.4, 144.3, 129.6, 128.6, 124.8,
123.9, 120.9, 117.7, 116.1, 112.3, 110.6, 61.6, 60.5, and 56.9. Anal.
calcd for C18H16N4O4¼C, 61.36; H, 4.58; N, 15.90; found; C, 61.73;
H, 4.80; N, 15.53.
2.3.8. 1-(2,4-Dinitrophenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-
one (4b)
Prepared according to general procedure B. Yield 92%, as brown-
ish orange crystals, mp >300 C, IR (KBr, cm1) max¼ 3418 (N–H),
3083 (C–H, sp2), 1690 (C¼O), 1533 and 1419 (C¼N). 1H NMR
(500MHz, DMSO-d6) d (ppm): 12.4 (s, 1H, NHCO), 9.08 (s, 1H, H-30),
8.86 (dd, 1H, J¼ 8.0 Hz, 2.5 Hz, H-50), 8.23 (d, 1H, J¼ 8.0 Hz, H-60),
7.43 (dd, 2H, J¼ 8.0 Hz, 2.5 Hz, H-6 and H-9), 6.99 (m, 2H, H-7 and
H-8), 13C NMR (500MHz, DMSO-d6) d (ppm): 151.5, 149.5, 148.1,
145.3, 144.5, 134.7, 129.3, 129.3, 128.6, 127.9, 123.4, 121.2, 120.1,
117.3, and 116.2. Anal. calcd for C15H8N6O6¼C, 51.14; H, 2.29; N,
23.86; found; C, 51.26; H, 2.29; N, 23.99.
2.3.9. 1-(2,4-Dihydroxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-
4(5H)-one (4c)
Prepared according to general procedure B. Yield 95%, as a brown
solid, mp >300 C, IR (KBr, cm1) max¼ 3403 (N–H), 3062 (C–H,
sp2), 1666 (C¼O), 1500 and 1425 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.13 (s, 1H, NHCO), 7.64 (s, 1H, H-30), 7.53 (d, 2H,
J¼ 10.5 Hz, H-50 and H-60), 7.15 (m, 4H, H-6 and -7H and H-8 and
H-9), 6.72 (s, 2H, OH). 13C NMR (500MHz, DMSO-d6) d (ppm):
151.8, 148.1, 144.3, 132.9, 129.1, 127.8, 124.5, 123.2, 116.9, 115.7,
102.1, and 101.2. Anal. calcd for C15H10N4O3¼C, 61.22; H, 3.43; N,
19.04; found; C, 61.09; H, 3.63; N, 19.32.
2.3.10. 1-(3,4-Dichlorophenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-
4(5H)-one (4d)
Prepared according to general procedure B. Yield 92.5%, as a
brownish orange solid, mp >300 C, IR (KBr, cm1) max¼ 3469
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(N–H), 3053 (C–H, sp2), 1679 (C¼O), 1517 and 1412 (C¼N). 1H
NMR (500MHz, DMSO-d6) d (ppm): 12.14 (s, 1H, NHCO), 8.06 (d,
1H, J¼ 2.0 Hz, H-20), 7.93 (d, 1H, J¼ 8.0 Hz, H-60), 7.75 (dd, 1H,
J¼ 10.0 Hz, 2.0 Hz, H-50), 7.1–7.4 (m, 4H, H-6 and H-7 and H-8 and
H-9); 13C NMR (500MHz, DMSO-d6) d (ppm): 152.3, 149.1, 144.9,
132.3, 132.1, 129.9, 128.4, 123.4, 117.7, and 116.9. Anal. calcd for
C18H18N4O4¼C, 54.40; H, 2.44; N, 16.92; found; C, 54.67; H, 2.46; N,
16.55.
2.3.11. 1-(Thiophen-2-yl)-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one
(4e)
Prepared according to general procedure B. Yield 39.6%, as a
beige solid, mp >300 C, IR (KBr, cm1) max¼ 3467 (N–H), 2923
(C–H, sp2), 1687 (C¼O), 1517 and 1413 (C¼N); 1H NMR (500MHz,
DMSO-d6) d (ppm): 12.14 (s, 1H, NHCO), 7.50 (m, 1H, H-20), 7.40 (m,
1H, H-30), 7.30 (m, 1H, H-40), 7.16–7.14 (m, 4H, H-6 and H-7 and H-
8 and H-9), 13C NMR (500MHz, DMSO-d6) d (ppm): 151.6, 144.6,
144.0, 133.2, 131.4, 129.4, 128.5, 128.1, 122.9, 120.7, 117.2, 116.4,
and 116.1. Anal. calcd for C13H18N4O4¼C, 58.20; H, 3.01; N, 20.88;
found; C, 58.66; H, 3.68; N, 20.90.
2.3.12. 1-(3-Methoxyphenyl)-[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-
one (4f)
Prepared according to general procedure B. Yield 55%, as a beige
solid, mp 286–288 C, IR (KBr, cm1) max¼ 3469 (N–H), 3049 (C–H,
sp2), 1686 (C¼O), 1587 and 1408 (C¼N). 1H NMR (500MHz, DMSO-
d6) d (ppm): 12.18 (s, 1H, NHCO), 8.29 (s, 1H, H-20), 7.80 (m, 1H,
H-60), 7.38 (m, 1H, H-50), 7.28–7.25 (m, 4H, H-6 and H-7 and H-8
and H-9), 6.93 (m, 1H, H-40), 3.82 (s, 3H, 30-OCH3).
13C NMR
(500MHz, DMSO-d6) d (ppm): 159.5, 151.9, 150.4, 144.2, 130.4,
127.7, 122.6, 121.9, 117.2, 116.8, 116.2, 115.1, and 55.6. Anal. calcd
for C16H12N4O2¼C, 65.75; H, 4.14; N, 19.17; found; C, 65.85; H, 4.40;
N, 18.78.
2.4. Biology: general methods
2.4.1. Inhibition of sPLA2 activity
The test of inhibitory activity of sPLA2 was performed as described
by Lobo de Araujo and Radvanyi41. Briefly, the substrate consisted
of 3.5mM lecithin in a mixture of 3mM NaTDC “Sodium
taurodeoxycholate”, 100mM NaCl, 10mM CaCl2, and 0.055mM red
phenol as colorimetric indicator in 100ml H2O. The pH of the reac-
tion mixture was adjusted to 7.6. The human group IB (pG-IB), IIA
(hG-IIA), V (hG-V), X (hG-X), and XII (hG-XII) sPLA2 were solubilised
in 10% acetonitrile at a concentration of 0.02 lg/lL. A volume of
10lL of these PLA2 solutions was incubated with 10 lL of each
compound for 20min at room temperature. Then, 1ml of the
PLA2 substrate was added, and the kinetic of hydrolysis was fol-
lowed during 5min by reading the optical density at 558 nm. The
inhibition percentage was calculated by comparison with a control
experiment (absence of compound).
2.4.2. a-Glucosidase inhibitory activity
The a-glucosidase inhibitory activity was performed by measuring
the liberation of 4-nitrophenol as described by Andrade-Cetto
et al.42. Briefly, 20 lL of control drug (quercetin), DMSO, or studied
compound (0.78–12.5 lg/ml) were mixed with 180 lL of the a-glu-
cosidase enzyme from Saccharomyces cerevisiae (Sigma, St. Louis,
MO) and incubated at 37 C for 2min. Then, 150 lL NPGP (4-nitro-
phenyl b-D-glucopyranoside) were added and the samples were
incubated at 37 C for about 20min. The assay media contained
10mM of potassium phosphate buffer, pH 6.9, 5mM of 4-NPGP,
and 2U of a-glucosidase. Quercetin also was used as positive con-
trol at the same concentration of the tested compound while
DMSO was used as the negative control. A microplate reader was
used for samples reading at 405 nm. The inhibition percentage
was calculated using the following equation: 100 – (X2
sampleX1 sample/X2 controlX1 control) 100 [where X1 is
the absorbance of the initial reading (T0), X2 is absorbance of the
final reading (T¼ 15min)]. IC50 values were determined by nonlin-
ear regression.
2.4.3. a-Amylase inhibitory activity
The a-amylase inhibitory activity was determined calorimetrically
according to Subramanian et al.43. Briefly, 4 U of a-amylase
enzyme (Sigma, St. Louis, MO) was incubated with 10 lL of each
compound (250–31.2 lg/ml), DMSO (negative control), or quer-
cetin (control drug used at the same compound concentrations),
at 37 C for 5min. Then, samples were mixed with 180 lL of the
Amylase Substrate (LabtestVR ) and incubated for 10min and the
first reaction was measured at 620 nm. Then, 100 lL of the react-
ive a-amylase (LabtestVR ) diluted in distilled water (1:1) and
150 lL of distilled water were added in the microplate and then
incubated at 37 C for 10min and the second reaction was
measured again. IC50 values were determined by nonlinear
regression. The a-amylase inhibition percentage was determined
using the following equation: % inhibition ¼100 – (A2
sample – X1 sample/X2 control X1 control) 100 where X1 is
the absorbance of the initial reading and X2 is the absorbance
of the final reading.
2.5. Molecular modelling
Molecular modelling was performed using Sybyl-X program. The
crystal structures of hG-X sPLA2 and a-glucosidase were down-
loaded from the RCSB website (www.rcsb.com) (PDB IDs: 5G3M
and 3W37 respectively). Protein preparation was performed
using the Biopolymer Preparation tool according to the follow-
ing parameters: H-Addition, H-Bond; Termini treatment, charged;
Protonation type of histidines, according to H-bonding donor or
acceptor; Side chain Bumps, Fix by Lovell method. At the end
of the preparation, brief Staged Energy Minimisation was per-
formed to the amino acid residues only using the following
parameters: Iterations, 100; Initial Minimisation, None; Force
Field, MMFF94s for a-glucosidase and AMBER7 FF02 for hG-X
sPLA2; Charges, MMFF94 a-glucosidase and for; Dielectric con-
stant, Constant; Non-Bonding Cutoff, 8.0 Å. The 3D structures
were generated by Concord protocol of Sybyl-X and saved as
SLN files to be used for docking. Docking was performed using
the Dock Ligands protocol of Sybyl-X using Surflex Docker. The
protomol was generated using the co-crystallised ligand. The
docked ligands were then inspected to compare the similarities
and differences in binding modes with the co-crystallised
ligands.
3. Results and discussion
3.1. Chemistry
Previously, we reported a small set of quinoxalinone derivatives as
antibacterial agents25. Therefore, we envisioned the quinoxalinone
nucleus as a common pharmacophore to develop compounds
that simultaneously inhibit sPLA2 and carbohydrate hydrolases.
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The compounds incorporate triazole or hydrazine–Schiff base moi-
eties which could coordinate calcium and could therefore serve as
a good starting point for sPLA2 inhibition26,27. Several novel sub-
stituted phenyl and thienyl derivatives were synthesised to explore
the compound SAR.
Several routes are available for synthesis of quinoxaline ring,
depending on the starting nuclei, to give either substituted qui-
noxaline or fused quinoxaline with other heterocyclic moieties
such as, triazole.
In our previous work, we have synthesised some quinoxaline
derivatives as shown in Scheme 1 starting from 1,4-dihydro-qui-
noxaline-2,3-dione 1 via the reaction between o-phenylenedi-
amine and oxalic acid28, then the later compound was used to
prepare 3-hydrazino-1H-quinoxalin-2-one 2 after reaction with
hydrazine hydrate as reported in the literature29. In the present
work, compound 2 was refluxed with derivatives of aromatic
benzaldehyde to afford six novel derivatives of 3-[N0-(substi-
tuted-benzylidene)-hydrazino]-1H-quinoxalin-2-one 3a–f30,31,
which then submitted the later compounds to the cyclisation
method in the presence of bromine in acetic acid, to give
another six novel derivatives of 1-(substituted-phenyl)-5H-
[1,2,4]triazolo[4,3-a]quinoxalin-4-ones 4a–f32 (see Figure 1 for the
synthesised derivatives).
3.2. Inhibition of phospholipase A2 (sPLA2), a-amylase, and
a-glucosidase
In order to evaluate the potential anti-inflammatory activity of the
12 studied compounds, we tested their inhibitory effects using
several human sPLA2 isozymes, pG-IIA, hG-V, hG-X, and hG-XII,
involved in the inflammatory process and porcine pG-IB sPLA2
which hydrolyses dietary phospholipids.
Data recorded in Table 1 show that compounds 3f, 4b, 4c, and
4d have the most promising results in inhibiting the catalytic
activities of all studied proinflammatory hG-IIA, hG-V, hG-X, and
GXII sPLA2. All of the studied compounds showed low micromolar
IC50 values against the different sPLA2 isozymes (IC50< 20 mM),
while having considerable selectivity towards the proinflammatory
sPLA2 isozymes over the pG-IB sPLA2 (Table 1). This may allow
future optimisation of the compounds to achieve absolute select-
ive activity towards proinflammatory sPLA2 isozymes. Some of the
compounds showed very potent submicromolar IC50 values
against proinflammatory sPLA2. For instance, compounds 3f, 4b,
4c, and 4d exhibited potent activities against sPLA2 isozymes hG-
IIA, hG-V, hG-X, and hG-XII (IC50 0.33–3 mM). However, the com-
pounds showed lower activity against pG-IB (IC50¼ 9.31 mM for
compound 3a) (Table 1).
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Figure 1. Chemical structures of series 3, series 4, and quercetin.
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Several reports on transgenic mice that overexpress group IIA,
group V, and group X sPLA2 have all shown an increase in foam
cell formation and atherosclerosis which has been reduced
through the use of an inhibitor of sPLA2 activity33–35. Thus, the
potential use of sPLA2 inhibitors for preventing many diseases like
cardiovascular events is being investigated which may provide
optimal benefit for these patients.
Concerning the pancreatic a-glucosidase enzyme (Table 2), the
studied compounds showed reasonable activities with satisfactory
IC50 values (IC50< 50 mM) (Table 2). Compound 3e inhibited the
enzyme and showed an IC50 value (9.99 ± 0.18 mM) comparable to
that recorded for quercetin (9.3 ± 0.66 mM). Several studies
reported that some foods and herbs have potential beneficial
effects on diabetic glycaemic control by inhibiting these
enzymes36,37. Hence, retardation of starch digestion by inhibition
of digestive enzymes plays a key role in the control of diabetes
and metabolic syndrome. The a-amylase activity of the studied
compounds was irrelevant (IC50> 200 mM) (Table 2). Compound
3e showed IC50 value of 395.84 ± 35.88 making it practically
inactive against a-amylase. The compounds were therefore unable
to inhibit a-amylase despite their promising activity against a-glu-
cosidase and sPLA2.
3.3. Molecular modelling
To investigate the binding mode of the synthesised inhibitors to
different enzyme targets, molecular modelling techniques were
deployed using the co-crystal structure of hG-X sPLA2 with the hit
compound 1 reported by Giordanetto et al.38. In this co-crystal
structure, the 4-benzylphenyl moiety of the inhibitor occupies a
hydrophobic pocket, while the amide group coordinates with the
catalytic site calcium. Manual docking of the compound 3f in the
active site of the crystal structure of hG-X sPLA2 (PDB ID: 5G3M)
shows the fulfilment of key interactions for the inhibition of this
enzyme. The hydrazine nitrogen forms a critical coordination bond
with the calcium ion present as a cofactor for the enzyme, similar
to that of the amide moiety of the co-crystallised inhibitor. This
interaction plays a central role in the inhibition of PLA2 activity38.
The 3-methoxyphenyl moiety of 3f occupies the same hydropho-
bic pocket occupied by the 4-benzylphenyl moiety of the co-crys-
tallised inhibitor. This pocket is composed of Ile2, Leu5, Val9, Leu
29, Ile94, Leu98, Tyr20, Cys43, Cys27, Pro17, and Ile18. The dra-
matic decrease in activity in 3c (IC50¼ 12.48 ± 0.87 mM) is proposed
to be due to the lack of hydrophobic substituents on the phenyl
ring and their replacement with two hydrophilic 2,4-dihydroxy
groups. This causes an obvious reduction in hydrophobic inter-
action with this pocket, forcing a hydrophilic moiety into a pocket
hydrophobic in nature. This conclusion is in accordance with the
activities of the rest of series 3, since the compounds bearing
hydrophobic groups show potent activities (<5 mM) varying
according to the nature of the substituent and their steric vol-
umes. It is worthy to note that the nitro groups of compound 3b
do not impart hydrophilicity to the molecule, but rather
“hydroneutrality” as shown by Sagawa and Shikata39. Compound
3e, which bears an unsubstituted 2-thienyl moiety, possesses the
least activity following 3c due to the low extent of hydrophobic
interactions. The quinoxalinone nucleus is found to penetrate a
tunnel formed by Leu29 and Lys61 beyond the metal pocket.
The carbonyl of the quinoxalinone moiety is able to form
two hydrogen bonds with Lys61 and Gly30 anchoring the com-
pound in position. Another hydrogen bond is also found between
the hydrazine nitrogen and the carboxylic acid group of Asp47
(Figure 2).
The docking of compound 4c in the active site of hG-X sPLA2
shows a binding mode astonishingly different from series 3. The
compounds do a 180 turn to put the quinoxalinone moiety in
the direction of the hydrophobic pocket. Hydrophobic interactions
are limited to Ile2, Leu29 and the side chain of Lys61 and the
penetration of the hydrophobic pocket is very shallow. The car-
bonyl oxygen forms a hydrogen bond with the nitrogen of Gly28.
The triazole moiety forms a monodentate coordination bond with
calcium, and hydrogen bonding with the nitrogen of Gly30. This
metal coordination is a strong interaction that is essential for fix-
ation of the compound and achieving inhibition. The 2,4-dihydrox-
yphenyl moiety is found to penetrate the Leu29-Lys61 tunnel and
establish two hydrogen bonds with the nitrogen of Gly30 and the
carboxylic group of Glu54. Due to the superficial penetration of
the hydrophobic pocket and very limited hydrophobic interactions,
the activity of the compounds is governed by the extent of hydro-
gen bonding, where the derivatives bearing hydrophilic and/or
hydrogen bonding groups (4b and 4c) or able to form halogen
bonds (4d) exhibit superior activities compared to those lacking
such groups (4a, 4e, and 4f). Thus, hG-X sPLA2 inhibition by series
4 is a function of the crucial metal coordination and the extent of
hydrogen bonding with the enzyme, but not due to hydrophobic
contact, which is rather very poor in this case.
Binding of the compound 3e to the active site of a-glucosidase
was investigated via molecular docking and compared to that of
quercetin using crystal structure of a-glucosidase co-crystallised
with the inhibitor acarbose (PDB ID: 3W37)40. The docking results
showed very comparable docking poses of the two ligands.
Table 1. Inhibitory activity of the title compounds against isoforms of sPLA2
expressed as IC50 (mM)±standard deviation.
IC50 (mM) Against Phospholipase
Compound pG-IB hG-IIA hG-V hG-X hG-XIIA
3a 9.31 ± 0.36 2.48 ± 0.28 1.46 ± 0.47 1.26 ± 0.05 3.04 ± 0.67
3b 10.72 ± 0.67 5.36 ± 0.73 1.12 ± 0.31 2.54 ± 0.42 2.28 ± 0.08
3c 13.33 ± 0.50 3.71 ± 0.27 9.45 ± 0.13 12.48 ± 0.87 6.75 ± 0.17
3d 13.50 ± 1.02 4.50 ± 0.33 5.70 ± 0.27 3.00 ± 0.63 10.50 ± 1.74
3e 10.72 ± 0.92 2.81 ± 0.33 6.28 ± 0.40 4.43 ± 1.03 3.81 ± 0.99
3f 12.40 ± 0.03 1.90 ± 0.30 1.22 ± 0.30 0.33 ± 0.06 0.84 ± 0.07
4a 14.19 ± 1.22 13.05 ± 0.05 11.30 ± 0.08 12.20 ± 0.47 13.25 ± 0.21
4b 13.62 ± 0.70 0.76 ± 0.01 1.53 ± 0.14 1.05 ± 0.08 2.58 ± 0.43
4c 14.78 ± 0.44 1.32 ± 0.16 1.05 ± 0.13 0.61 ± 0.03 0.91 ± 0.05
4d 14.49 ± 0.87 1.81 ± 0.04 3.04 ± 0.57 2.71 ± 0.07 1.41 ± 0.07
4e 16.77 ± 0.93 16.81 ± 0.41 18.63 ± 0.56 17.89 ± 0.94 18.63 ± 1.33
4f 15.97 ± 1.71 17.10 ± 0.41 15.80 ± 0.85 14.36 ± 0.52 15.77 ± 1.29
Oleanolic acid 10.40 ± 1.16 11.50 ± 0.76 16.42 ± 1.53 16.531 ± 1.38 13.14 ± 0.92
All experiments were performed in duplicate.
Table 2. Inhibitory activity of the title compounds against a-glucosidase and
a-amylase expressed as IC50 (mM)± standard deviation.
IC50 (mM)
Compound a-Glucosidase a-Amylase
3a 42.33 ± 3.38 428.93 ± 31.04
3b 14.11 ± 2.08 296.38 ± 26.81
3c 14.18 ± 1.51 300.38 ± 26.32
3d 22.51 ± 2.01 735.36 ± 52.52
3e 9.99 ± 0.18 395.84 ± 35.88
3f 13.93 ± 2.03 492.68 ± 46.20
4a 14.75 ± 2.12 638.56 ± 30.65
4b 22.99 ± 2.83 806.19 ± 91.97
4c 12.91 ± 1.69 1087.43 ± 74.08
4d 12.98 ± 1.20 431.81 ± 34.72
4e 36.52 ± 2.98 1330.65 ± 82
4f 24.29 ± 3.76 413.95 ± 52.68
Quercetin 9.93 ± 0.66 479.75 ± 18.86
All experiments were performed in duplicate.
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Figure 2. Binding mode of 3f and 4c to hG-X sPLA2. (A) Compound 3f (magenta) and (C) compound 4c (orange) in the binding pocket of hG-X sPLA2 showing hydro-
gen bonds, calcium coordination (purple), and interacting residues. (B) Compound 3f (magenta) and (D) compound 4c (orange) in the binding pocket of hG-X sPLA2
showing a lipophilic potential surface of the pocket.
Figure 3. Binding mode of quercetin and 3e to a-glucosidase. (A) Quercetin (orange) and (C) compound 3e (magenta) in the binding pocket of a-glucosidase showing
hydrogen bonds and interacting residues. (B) Quercetin (orange) and (D) compound 3e (magenta) in the binding pocket of a-glucosidase showing a lipophilic potential
surface of the pocket.
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Both compounds were able to achieve hydrogen bonding with
Arg552, similar to that found in the co-crystal structure. Quercetin
was able to achieve three other hydrogen bonding interactions
with the carboxylic group of Asp568 and Asp357 and the imid-
azole of His626 while 3e formed another hydrogen bond with
Asp469 via its amidic quinoxalinone nitrogen. Interestingly, both
quercetin and 3e formed an impressive number of hydrophobic
interactions. Compound 3e was shown to insert its quinoxalinone
benzene ring into a hydrophobic pocket composed of Ile358,
Ile396, Trp467, Trp329, and Trp432. The benzene ring of the qui-
noxalinone nucleus was able to form a T-shaped p–p stacking
with the indole ring of Trp329. The compound is bent in an L-
shape to achieve another T-shaped p–p stacking with Trp329
through its thiophene ring. The thiophene also forms hydrophobic
contact with the phenyl of Phe601. Quercetin achieved a T-shaped
p–p stacking with another tryptophan residue, Trp432. The binding
of quercetin also showed hydrophobic contacts with Phe601 and
Trp329. This finding is in accordance with the report by Li et al.
where the binding of quercetin to a-glucosidase was shown to be
governed by hydrophobic interaction through a kinetic study23.
Compound 3e also shows comparable activity to quercetin and a
variety of hydrophobic interactions. Compound 3a showing the
least potency did not form any hydrogen bonds with the enzyme,
but only hydrophobic interactions with Trp467 and Trp565 and a
T-shaped p–p stacking with Trp329. This may be due to the steric
effects of the 3 adjacent methoxy groups (Figure 3).
4. Conclusions
The aim of this work was to synthesise quinoxaline derivatives and
to evaluate them in vitro as inhibitors against secretory phospholip-
ase A2 (sPLA2) and test their activity against carbohydrate hydrolases
(a-glucosidase and a-amylase). Twelve compounds were synthesised
based on the 2,3-quinoxaline and triazoloquinoxaline derivatives,
where 11 compounds were novel. Regarding the inhibition of proin-
flammatory sPLA2 isozymes, promising and potent results were
recorded for compounds 3f, 4b, 4c, and 4d, while exhibiting consid-
erably lower activities against GI-B sPLA2. Compound 3e was the
most active compound inhibiting the a-glucosidase with potency
comparable to that of the control quercetin. Compound 3e also
showed irrelevant activity towards a-amylase. The mechanism of
action of the compounds was investigated through molecular model-
ling and correlated to the practically obtained results. Despite the
absence of activity against a-amylase, our compounds were able to
dually inhibit a-glucosidase and sPLA2 isozymes. This work opens a
new area for developing of small molecules that could simultan-
eously modulate postprandial blood glucose and inhibit proathero-
genic sPLA2 isozymes with the aim of controlling hyperglycaemia
and cardiovascular complications in diabetic patients.
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